Clene Inc. (CLNN)
| Market Cap | 27.65M |
| Revenue (ttm) | 342,000 |
| Net Income (ttm) | -39.40M |
| Shares Out | 8.59M |
| EPS (ttm) | -5.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,569 |
| Open | 3.170 |
| Previous Close | 3.180 |
| Day's Range | 3.150 - 3.260 |
| 52-Week Range | 3.090 - 9.200 |
| Beta | 0.26 |
| Analysts | Strong Buy |
| Price Target | 55.25 (+1,615.84%) |
| Earnings Date | Mar 24, 2025 |
About CLNN
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 ... [Read more]
Financial Performance
In 2024, Clene's revenue was $342,000, a decrease of -47.71% compared to the previous year's $654,000. Losses were -$39.40 million, -20.41% less than in 2023.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CLNN stock is "Strong Buy." The 12-month stock price forecast is $55.25, which is an increase of 1,615.84% from the latest price.
News
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bioph...
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage
Clene to Present at the 37TH Annual Roth Conference
SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bioph...
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Rob Etherington, CEO, and Morgan Brown, CFO, of Clene Inc., will be presenting at this year's Investor Summit Virtual on March 11th. About Clene In...
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers APST Research data includes thousands of people living with ALS including...
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmac...
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bioph...
Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmac...
IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.
LOS ANGELES, Aug. 08, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the ...
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
SALT LAKE CITY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, July 12, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS
SALT LAKE CITY, July 11, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene Announces 1-for-20 Reverse Stock Split
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference
SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
SALT LAKE CITY, June 21, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
SALT LAKE CITY, June 18, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceu...
Clene to Present at Upcoming May Conferences
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biophar...
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
SALT LAKE CITY, May 08, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopha...
Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharma...
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
SALT LAKE CITY, March 15, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmac...
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
SALT LAKE CITY, March 13, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmac...
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
SALT LAKE CITY, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene says FDA finds ALS drug data not enough for accelerated nod
Dec 21 (Reuters) - Clene (CLNN.O) said on Thursday data on its therapy to treat a type of neurological disease did not meet the U.S. drug regulator's target for accelerated approval.